<DOC>
	<DOCNO>NCT00082732</DOCNO>
	<brief_summary>RATIONALE : A low-fat , high-fiber diet include soy protein may prevent disease progression patient hormone-refractory prostate cancer . Nutrition counseling may help motivate patient follow diet . PURPOSE : Randomized phase I trial study effectiveness behavior-based dietary intervention , receive nutrition counseling , help patient hormone-refractory prostate cancer follow low-fat , high-fiber , soy-supplemented diet .</brief_summary>
	<brief_title>Behavior-Based Dietary Intervention Treating Patients With Hormone-Refractory Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether behavior-based dietary intervention motivate patient hormone-refractory prostate cancer adopt maintain dietary pattern include &lt; 20 % energy fat , &gt; 25 g fiber , 80 g soy protein powder . - Compare bioavailable level testosterone patient treat behavior-based dietary intervention v observation . - Determine whether dietary intervention decrease stabilize rise serum prostate-specific antigen level patient . - Determine whether dietary intervention improve disease-specific survival , mediate reduce bioavailable level testosterone , patient . - Determine impact positive intervention outcome androgen receptor patient treat dietary intervention . OUTLINE : This randomize , control , pilot , multicenter study . Patients randomize 1 2 treatment arm . All patient receive nutritional counseling healthy diet . Patients also keep food diary study participation . - Arm I ( dietary intervention ) : Patients receive dietary intervention comprise nutritional counseling low-fat , high-fiber , soy supplement diet behavior-based activity , goal-setting , contracting , stimulus control , weekly 6 week , every 3 week 33 week , week 44 , 48 , 52 . Treatment continue absence disease progression unacceptable toxicity . - Arm II ( observation ) : Patients undergo observation every 6 week 36 week every 8 week 18 week . PROJECTED ACCRUAL : A total 92 patient ( 46 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate No small cell component No histologically confirm and/or demonstrable metastatic locally recurrent disease bone scan , chest xray , compute tomography ( CT ) scan , transrectal ultrasound No clinical symptom within past 90 day Documented biochemical failure radical prostatectomy Prostatespecific antigen must initially nadired undetectable level ( &lt; 0.1 ng/mL ) prostatectomy AND currently rise ( 0.340.0 ng/mL ) Serum testosterone &gt; 100 ng/dL PATIENT CHARACTERISTICS : Age Any age Performance status Zubrod 01 Life expectancy At least 1 year Hematopoietic Not specify Hepatic Not specify Renal Not specify Other No know allergic reaction milk soy product PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 1 year since prior chemotherapy Endocrine therapy More 1 year since prior hormonal therapy Radiotherapy Not specify Surgery See Disease Characteristics</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
</DOC>